Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

BACKGROUND: Many patients with multiple sclerosis (MS) experience suboptimal disease control despite the use of disease-modifying therapy (DMT). OBJECTIVE: To assess the efficacy and safety of ocrelizumab (OCR) in patients with relapsing-remitting MS (RRMS) and suboptimal response to prior DMTs. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock-Guttman, Bianca, Bermel, Robert, Cutter, Gary, Freedman, Mark S, Leist, Thomas P, Ma, Xiaoye, Kile, Deidre, Musch, Bruno, Reder, Anthony T, Wolinsky, Jerry S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978461/
https://www.ncbi.nlm.nih.gov/pubmed/34382875
http://dx.doi.org/10.1177/13524585211035740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978461/
https://www.ncbi.nlm.nih.gov/pubmed/34382875
http://dx.doi.org/10.1177/13524585211035740

Ejemplares similares